In the present study, the anti-tumor efficacy of AZD3759 against glioma and its underlying mechanism was investigated to provide more clinical evidence for the application of AZD3759 for the treatment of patients with glioma and EGFR-sensitive mutations in the clinic. Here, EGFR is linked to central nervous system cancer.